These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

778 related articles for article (PubMed ID: 28249894)

  • 21. CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience.
    Frerichs KA; Nagy NA; Lindenbergh PL; Bosman P; Marin Soto J; Broekmans M; Groen RWJ; Themeli M; Nieuwenhuis L; Stege C; Nijhof IS; Mutis T; Zweegman S; Lokhorst HM; van de Donk NWCJ
    Expert Rev Clin Immunol; 2018 Mar; 14(3):197-206. PubMed ID: 29465271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment.
    Strauss L; Bergmann C; Szczepanski M; Gooding W; Johnson JT; Whiteside TL
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4345-54. PubMed ID: 17671115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stimulation of α7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro.
    Wang DW; Zhou RB; Yao YM; Zhu XM; Yin YM; Zhao GJ; Dong N; Sheng ZY
    J Pharmacol Exp Ther; 2010 Dec; 335(3):553-61. PubMed ID: 20843956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4+CD25+ Tregs.
    Bocian K; Borysowski J; Wierzbicki P; Wyzgal J; Klosowska D; Bialoszewska A; Paczek L; Górski A; Korczak-Kowalska G
    Nephrol Dial Transplant; 2010 Mar; 25(3):710-7. PubMed ID: 19903662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural and inducible Tregs in swine: Helios expression and functional properties.
    Käser T; Mair KH; Hammer SE; Gerner W; Saalmüller A
    Dev Comp Immunol; 2015 Apr; 49(2):323-31. PubMed ID: 25511662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.
    Martin TG; Corzo K; Chiron M; Velde HV; Abbadessa G; Campana F; Solanki M; Meng R; Lee H; Wiederschain D; Zhu C; Rak A; Anderson KC
    Cells; 2019 Nov; 8(12):. PubMed ID: 31779273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High concentrations of atorvastatin reduce in-vitro function of conventional T and regulatory T cells.
    Rodríguez-Perea AL; Rojas M; Velilla-Hernández PA
    Clin Exp Immunol; 2019 May; 196(2):237-248. PubMed ID: 30638266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
    Adams HC; Stevenaert F; Krejcik J; Van der Borght K; Smets T; Bald J; Abraham Y; Ceulemans H; Chiu C; Vanhoof G; Usmani SZ; Plesner T; Lonial S; Nijhof I; Lokhorst HM; Mutis T; van de Donk NWCJ; Sasser AK; Casneuf T
    Cytometry A; 2019 Mar; 95(3):279-289. PubMed ID: 30536810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunosuppressive drugs on inducing Ag-specific CD4(+)CD25(+)Foxp3(+) Treg cells during immune response in vivo.
    Wu T; Zhang L; Xu K; Sun C; Lei T; Peng J; Liu G; Wang R; Zhao Y
    Transpl Immunol; 2012 Aug; 27(1):30-8. PubMed ID: 22613676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different immunosuppressive combinations on T-cell regulation in renal transplant recipients.
    Fourtounas C; Dousdampanis P; Sakellaraki P; Rodi M; Georgakopoulos T; Vlachojannis JG; Mouzaki A
    Am J Nephrol; 2010; 32(1):1-9. PubMed ID: 20484893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fine-tuning of regulatory T cell function: the role of calcium signals and naive regulatory T cells for regulatory T cell deficiency in multiple sclerosis.
    Schwarz A; Schumacher M; Pfaff D; Schumacher K; Jarius S; Balint B; Wiendl H; Haas J; Wildemann B
    J Immunol; 2013 May; 190(10):4965-70. PubMed ID: 23576680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. INFα-2b inhibitory effects on CD4(+)CD25(+)FOXP3(+) regulatory T cells in the tumor microenvironment of C57BL/6 J mice with melanoma xenografts.
    Yu Y; Huang R; Zong X; He X; Mo W
    BMC Cancer; 2016 Jul; 16():397. PubMed ID: 27389040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.
    Kassem S; Diallo BK; El-Murr N; Carrié N; Tang A; Fournier A; Bonnevaux H; Nicolazzi C; Cuisinier M; Arnould I; Sidhu SS; Corre J; Avet-Loiseau H; Teillaud JL; van de Velde H; Wiederschain D; Chiron M; Martinet L; Virone-Oddos A
    Blood; 2022 Feb; 139(8):1160-1176. PubMed ID: 35201323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy.
    Scott GB; Carter C; Parrish C; Wood PM; Cook G
    Cell Immunol; 2015 Sep; 297(1):1-9. PubMed ID: 26051632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of murine and human Treg subsets in inflammatory bowel disease.
    Sun X; He S; Lv C; Sun X; Wang J; Zheng W; Wang D
    Mol Med Rep; 2017 Sep; 16(3):2893-2898. PubMed ID: 28677759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Siplizumab selectively depletes effector memory T cells and promotes a relative expansion of alloreactive regulatory T cells in vitro.
    Podestà MA; Binder C; Sellberg F; DeWolf S; Shonts B; Ho SH; Obradovic A; Waffarn E; Danzl N; Berglund D; Sykes M
    Am J Transplant; 2020 Jan; 20(1):88-100. PubMed ID: 31319439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Daratumumab prevents programmed death ligand-1 expression on antigen-presenting cells in de novo multiple myeloma.
    Stocker N; Gaugler B; Ricard L; de Vassoigne F; Marjanovic Z; Mohty M; Malard F
    Cancer Med; 2020 Mar; 9(6):2077-2084. PubMed ID: 31991058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of peripheral blood T-cell subsets and regulatory T-cells in multiple myeloma patients.
    Huang LQ; Wang JX; He K; Jiang YZ; Wei ZL; Huang DP; Chu LL
    Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):113-117. PubMed ID: 29729703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
    Drent E; Groen RW; Noort WA; Themeli M; Lammerts van Bueren JJ; Parren PW; Kuball J; Sebestyen Z; Yuan H; de Bruijn J; van de Donk NW; Martens AC; Lokhorst HM; Mutis T
    Haematologica; 2016 May; 101(5):616-25. PubMed ID: 26858358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Partial CD25 Antagonism Enables Dominance of Antigen-Inducible CD25
    Wilkinson DS; Ghosh D; Nickle RA; Moorman CD; Mannie MD
    Front Immunol; 2017; 8():1782. PubMed ID: 29312311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.